Codexis Signs Strategic Collaboration and License Agreement with Takeda to Advance Novel Gene Therapies for Rare Genetic Disorders
Codexis, Inc. (CDXS)
Last codexis, inc. earnings: 2/27 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.codexis.com/investors
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces the signing of a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (Takeda) for the research and development of novel gene therapies for certain disease indications, including the treatment of lysosomal storage disorders and blood factor deficiencies. Under the terms of the agreement, Codexis will generate novel gene sequences encoding protein variants tailored to enhance efficacy as a result of increased activity, stability, and cellular uptake using its CodeEvolver® protein engineering platform. Takeda will combine these improved transgenes with its gene therapy capabilities to generate novel candidates for the treatment of rare genetic disorders. “Our CodeEvolver® platform technology enables the rapid engineering of novel genetic sequences that encode more efficacious proteins.
Show less
Read more
Impact Snapshot
Event Time:
CDXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDXS alerts
High impacting Codexis, Inc. news events
Weekly update
A roundup of the hottest topics
CDXS
News
- Codexis, Inc. (NASDAQ: CDXS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $11.00 price target on the stock.MarketBeat
- Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics [Yahoo! Finance]Yahoo! Finance
- Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi TherapeuticsGlobeNewswire
- Codexis Announces Appointment of Raymond De Vré, PhD, to Board of DirectorsGlobeNewswire
- Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics [Yahoo! Finance]Yahoo! Finance
CDXS
Earnings
- 10/31/24 - Miss
CDXS
Sec Filings
- 11/14/24 - Form SCHEDULE
- 11/12/24 - Form 4
- 11/12/24 - Form 3
- CDXS's page on the SEC website